As Shanghai seeks to develop into an international biopharma hub, the local government is encouraging commercial medical insurers to cover more innovative drugs in their products. The policy aims to provide an alternative solution to dominant pricing by the national public payer, which often imposes deep discounts on novel drugs in exchange for reimbursement coverage.